The word on Ivermectin as a potential approach to therapeutically countering COVID-19 is now getting out there—this time with Nikkei Asian Review. TrialSite News has followed the progression of the off-label approach of this anti-parasite drug carefully. Most recently, University of Kentucky announced that the common, cheap drug would be used in a clinical trial. Now a Japanese media offers updates including the fact that Kitasato University is in discussions with Merck's Japanese subsidiary to consider a clinical trial there.
The Japanese Connection
A Kitasato University Professor named Satoshi Omura, a 2015 Nobel Prize winner, developed the original findings that was thereafter used to create the drug. Now Nikkei Asian Review reports that the Tokyo-based university (Kitasato University) will consider a clinical trial using the drug to target COVID-19.
The Australian Spark
It was, of course, a group of researchers in Australia that was the catalyst for this emerging global interest in Ivermectin. A team from Monash University’s Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity at Royal Melbourne Hospital published a study...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).